Canada Pension Plan Investment Board grew its position in shares of Intrexon Corp (NYSE:XON) by 23.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 474,400 shares of the biotechnology company’s stock after acquiring an additional 90,400 shares during the quarter. Canada Pension Plan Investment Board owned about 0.37% of Intrexon worth $8,169,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in XON. Royal Bank of Canada grew its stake in Intrexon by 47.8% in the 1st quarter. Royal Bank of Canada now owns 22,021 shares of the biotechnology company’s stock worth $339,000 after buying an additional 7,117 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in Intrexon by 8.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 69,880 shares of the biotechnology company’s stock worth $974,000 after buying an additional 5,579 shares in the last quarter. State of Wisconsin Investment Board grew its stake in Intrexon by 475.6% in the 2nd quarter. State of Wisconsin Investment Board now owns 74,100 shares of the biotechnology company’s stock worth $1,033,000 after buying an additional 61,227 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Intrexon by 13.0% in the 2nd quarter. Rhumbline Advisers now owns 67,537 shares of the biotechnology company’s stock valued at $941,000 after purchasing an additional 7,784 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Intrexon by 18.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 278,611 shares of the biotechnology company’s stock valued at $3,884,000 after purchasing an additional 43,310 shares in the last quarter. Institutional investors own 84.92% of the company’s stock.
In other news, SVP Joel D. Liffman sold 79,000 shares of the company’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $14.59, for a total value of $1,152,610.00. Following the completion of the sale, the senior vice president now owns 79,500 shares of the company’s stock, valued at approximately $1,159,905. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 48.20% of the stock is currently owned by corporate insiders.
A number of brokerages have recently issued reports on XON. ValuEngine raised shares of Intrexon from a “sell” rating to a “hold” rating in a research note on Monday, September 24th. JMP Securities upped their price objective on shares of Intrexon from $42.00 to $43.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 10th. Finally, Zacks Investment Research cut shares of Intrexon from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $29.67.
Shares of Intrexon stock opened at $9.06 on Friday. Intrexon Corp has a 52-week low of $8.92 and a 52-week high of $20.16.
Intrexon (NYSE:XON) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.21). The firm had revenue of $32.45 million for the quarter, compared to the consensus estimate of $35.98 million. During the same period last year, the business earned ($0.33) earnings per share. The business’s quarterly revenue was down 29.5% compared to the same quarter last year.
ILLEGAL ACTIVITY WARNING: “Intrexon Corp (XON) Shares Bought by Canada Pension Plan Investment Board” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/intrexon-corp-xon-shares-bought-by-canada-pension-plan-investment-board.html.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Further Reading: Compound Interest and Why It Matters When Investing
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.